+

WO2006039268A3 - Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations - Google Patents

Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations Download PDF

Info

Publication number
WO2006039268A3
WO2006039268A3 PCT/US2005/034587 US2005034587W WO2006039268A3 WO 2006039268 A3 WO2006039268 A3 WO 2006039268A3 US 2005034587 W US2005034587 W US 2005034587W WO 2006039268 A3 WO2006039268 A3 WO 2006039268A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipophilic drugs
containing vitamin
formulations
efflux inhibition
pharmaceutical formulations
Prior art date
Application number
PCT/US2005/034587
Other languages
English (en)
Other versions
WO2006039268A2 (fr
Inventor
John Anthony Hyatt
George Chester Zima
Kevin Joseph Edgar
Lisa Tonner Navarro
Claus-Michael Lehr
Eva-Maria Collnot
Andy Hugh Singleton
Christiane Baldes
Ulrich Friedrich Schafer
Michael Fitzpatrick Wempe
Original Assignee
Eastman Chem Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chem Co filed Critical Eastman Chem Co
Priority to EP05803721A priority Critical patent/EP1793806A2/fr
Priority to JP2007534708A priority patent/JP2008514714A/ja
Publication of WO2006039268A2 publication Critical patent/WO2006039268A2/fr
Publication of WO2006039268A3 publication Critical patent/WO2006039268A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés et des compositions permettant d'accroître la biodisponibilité de médicaments lipophiles et, plus précisément, des médicaments lipophiles de dispersion, au moyen de bioactivateurs n'engendrant pas d'inhibition de l'écoulement ou engendrant un degré souhaité d'inhibition de l'écoulement. L'invention concerne également des procédés de fabrication et d'utilisation de ces compositions.
PCT/US2005/034587 2004-09-30 2005-09-29 Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations WO2006039268A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05803721A EP1793806A2 (fr) 2004-09-30 2005-09-29 Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations
JP2007534708A JP2008514714A (ja) 2004-09-30 2005-09-29 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61489104P 2004-09-30 2004-09-30
US60/614,891 2004-09-30

Publications (2)

Publication Number Publication Date
WO2006039268A2 WO2006039268A2 (fr) 2006-04-13
WO2006039268A3 true WO2006039268A3 (fr) 2006-07-27

Family

ID=36142996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034587 WO2006039268A2 (fr) 2004-09-30 2005-09-29 Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations

Country Status (4)

Country Link
EP (1) EP1793806A2 (fr)
JP (1) JP2008514714A (fr)
CN (1) CN101031284A (fr)
WO (1) WO2006039268A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
EP2398476B1 (fr) 2009-02-23 2018-02-07 Nanorx, Inc. Nanoparticules de policosanol
US9034383B2 (en) 2010-08-23 2015-05-19 NanoRx, Inc. Policosanol nanoparticles
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
KR20220119647A (ko) * 2019-12-20 2022-08-30 아이도시아 파마수티컬즈 리미티드 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세트아미드를 포함하는 제약 조성물
BR112022011786A2 (pt) * 2019-12-20 2022-08-30 Intervet Int Bv Composição farmacêutica de pirazol

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035587A1 (fr) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions contenant un inhibiteur de la protease du vih tel que le vx 478 et un compose hydrosoluble de vitamine e tel que la vitamine e-tpgs
WO1998008490A1 (fr) * 1996-09-01 1998-03-05 Pharmos Corporation Coprecipites solides augmentant la biodisponibilite de substances lipophiles
WO2000061189A2 (fr) * 1999-04-02 2000-10-19 National Research Council Of Canada Compositions hydrosolubles de composes lipophiles bioactifs
US20010029264A1 (en) * 1998-03-10 2001-10-11 Mcchesney-Harris Lisa L. Novel methods and compositions for delivery of taxanes
WO2003013474A1 (fr) * 2001-08-09 2003-02-20 Jagotec Ag Preparations nanoparticulaires constituees de fenofibrate
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
EP1464341A1 (fr) * 2003-04-03 2004-10-06 Visufarma S.R.L. Formulation hydrosoluble comprénant de l'ubiquinone pour utilisation oculaire

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035587A1 (fr) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions contenant un inhibiteur de la protease du vih tel que le vx 478 et un compose hydrosoluble de vitamine e tel que la vitamine e-tpgs
WO1998008490A1 (fr) * 1996-09-01 1998-03-05 Pharmos Corporation Coprecipites solides augmentant la biodisponibilite de substances lipophiles
US20010029264A1 (en) * 1998-03-10 2001-10-11 Mcchesney-Harris Lisa L. Novel methods and compositions for delivery of taxanes
WO2000061189A2 (fr) * 1999-04-02 2000-10-19 National Research Council Of Canada Compositions hydrosolubles de composes lipophiles bioactifs
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
WO2003013474A1 (fr) * 2001-08-09 2003-02-20 Jagotec Ag Preparations nanoparticulaires constituees de fenofibrate
EP1464341A1 (fr) * 2003-04-03 2004-10-06 Visufarma S.R.L. Formulation hydrosoluble comprénant de l'ubiquinone pour utilisation oculaire

Also Published As

Publication number Publication date
CN101031284A (zh) 2007-09-05
EP1793806A2 (fr) 2007-06-13
JP2008514714A (ja) 2008-05-08
WO2006039268A2 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2009108828A3 (fr) Formes d'aprépitant avec une meilleure solubilité et leurs compositions pharmaceutiques
WO2004043363A8 (fr) Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
WO2005020913A3 (fr) Preparations, conjugues, et combinaisons de medicaments dans le traitement de neoplasmes
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2007047253A3 (fr) Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole
WO2004016277A3 (fr) Ameliorations apportees a l'extraction de composants pharmaceutiquement actifs issus de vegetaux
WO2005020962A8 (fr) Forme galenique huileuse auto-nanoemulsifiante pour l'administration de medicaments difficilement hydrosolubles
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
TW200616640A (en) Novel pharmaceutical formulations of active principles
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
WO2004093800A3 (fr) Derives de thyronamine et analogues et des methodes d'utilisation de ces composes
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
WO2003086293A3 (fr) Preparation pharmaceutique de masquage de gout
WO2004105773A3 (fr) Utilisation de s1p
WO2006044805A3 (fr) Preparations pharmaceutiques pour lesquelles le risque d'abus est reduit
WO2001074790A3 (fr) Nouveaux composes pour ameliorer la chimiotherapie
WO2003020214A3 (fr) Composes derives des acides biliaires permettant d'ameliorer l'absorption orale et la biodisponibilite systemique de medicaments
WO2006039268A3 (fr) Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations
WO2003068157A3 (fr) Inhibiteurs de kinase et leurs procedes d'utilisation
WO2007133711A3 (fr) Compositions pharmaceutiques pour médicaments irritants pour les veines
WO2007086911A3 (fr) Formulations nanoparticulaires stables
WO2004047798A3 (fr) Formulations de finastéride
WO2008004100A9 (fr) Composés thérapeutiques
WO2005030142A3 (fr) Formulations de rifalazil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005803721

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007534708

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580033202.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005803721

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载